Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
Hall, Terence G, Yu, Yi, Eathiraj, Sudharshan, Wang, Yunxia, Savage, Ronald E, Lapierre, Jean-Marc, Schwartz, Brian, Abbadessa, Giovanni
Published in PloS one (14.09.2016)
Published in PloS one (14.09.2016)
Get full text
Journal Article
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Mazzaferro, Vincenzo, El-Rayes, Bassel F, Droz Dit Busset, Michele, Cotsoglou, Christian, Harris, William P, Damjanov, Nevena, Masi, Gianluca, Rimassa, Lorenza, Personeni, Nicola, Braiteh, Fadi, Zagonel, Vittorina, Papadopoulos, Kyriakos P, Hall, Terence, Wang, Yunxia, Schwartz, Brian, Kazakin, Julia, Bhoori, Sherrie, de Braud, Filippo, Shaib, Walid L
Published in British journal of cancer (01.01.2019)
Published in British journal of cancer (01.01.2019)
Get full text
Journal Article
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yu, Yi, Savage, Ronald E, Eathiraj, Sudharshan, Meade, Justin, Wick, Michael J, Hall, Terence, Abbadessa, Giovanni, Schwartz, Brian
Published in PloS one (15.10.2015)
Published in PloS one (15.10.2015)
Get full text
Journal Article
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models
Chilà, Rosaria, Hall G., Terence, Abbadessa, Giovanni, Broggini, Massimo, Damia, Giovanna
Published in Translational oncology (01.04.2017)
Published in Translational oncology (01.04.2017)
Get full text
Journal Article
Abstract A034: The use of biomarkers and ctDNA in a phase 1 trial of ARQ 751
Pant, Shubham, Lamar, Maria, Kazakin, Julia, Savage, Ronald, Schwartz, Brian, hall, terence
Published in Molecular cancer therapeutics (01.12.2019)
Published in Molecular cancer therapeutics (01.12.2019)
Get full text
Journal Article
Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC)
Juric, Dejan, Richardson, Debra L., Bashir, Babar, Sharma, Manish, Papadopoulos, Kyriakos P., Mathews, Sara, Hodgson, Graeme, Henry, Susan, Paul, Sofia, Hall, Terence, Roth, David A., Kelly, Michael, Abdul Malak, Tanya, Klimek, Virginia
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Abstract 4797: In vitro and in vivo effect of ARQ 531 on Trk family kinases
Yu, Yi, Schwartz, Gabi, Schamber, Pascal, Savage, Ron E., Eathiraj, Sudharshan, Hall, Terence, Schwartz, Brian
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article
Electrostatic Dissipation in 3D-Printable Silicone
Armas, Jeremy A., Ford, Michael J., Foster, Kenton P., Hall, Terence, Loeb, Colin K., Schmidt, Spencer, Williams, Stanley F., Baron, Kathlyn L., Pérez Pérez, Lemuel X., Xie, Fangyou, Bryson, Taylor M., Lenhardt, Jeremy M.
Published in ACS applied materials & interfaces (03.09.2024)
Published in ACS applied materials & interfaces (03.09.2024)
Get full text
Journal Article
Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel
Bashir, Babar, Sharma, Manish, Juric, Dejan, Papadopoulos, Kyriakos P., Hamilton, Erika P., Richardson, Debra L., Shapiro, Geoffrey, Sahai, Vaibhav, Mettu, Niharika B., Wainberg, Zev A., Alese, Olatunji B., Dragovich, Tomislav, Hodgson, Graeme, Henry, Susan, Hall, Terence, Paul, Sofia, Roth, David A., Kelly, Michael, Abdul Malak, Tanya, Klimek, Virginia
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3
Balek, Lukas, Gudernova, Iva, Vesela, Iva, Hampl, Marek, Oralova, Veronika, Kunova Bosakova, Michaela, Varecha, Miroslav, Nemec, Pavel, Hall, Terence, Abbadessa, Giovanni, Hatch, Nan, Buchtova, Marcela, Krejci, Pavel
Published in Bone (New York, N.Y.) (01.12.2017)
Published in Bone (New York, N.Y.) (01.12.2017)
Get full text
Journal Article
Abstract LB-018: ARQ 531, a novel and reversible inhibitor of Bruton's tyrosine kinase, displays favorable oral bioavailability and exposure in patients with B-cell malignancies
Hall, Terence, Yu, Yi, Eathiraj, Sudharshan, Stephens, Deborah, Flinn, Ian, Woyach, Jennifer, Schwartz, Brian, Savage, Ronald E.
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma
Raggi, Chiara, Fiaccadori, Karim, Pastore, Mirella, Correnti, Margherita, Piombanti, Benedetta, Forti, Elisa, Navari, Nadia, Abbadessa, Giovanni, Hall, Terence, Destro, Annarita, Di Tommaso, Luca, Roncalli, Massimo, Meng, Fanyin, Glaser, Shannon, Rovida, Elisabetta, Peraldo-Neia, Caterina, Olaizola, Paula, Banales, Jesus M., Gerussi, Alessio, Elvevi, Alessandra, Droz dit Busset, Michele, Bhoori, Sherrie, Mazzaferro, Vincenzo, Alpini, Gianfranco, Marra, Fabio, Invernizzi, Pietro
Published in The American journal of pathology (01.10.2019)
Published in The American journal of pathology (01.10.2019)
Get full text
Journal Article
Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models
Chilà, Rosaria, Guffanti, Federica, Hall, Terence, Ricci, Francesca, Broggini, Massimo, Damia, Giovanna
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Get full text
Journal Article
Abstract B185: ARQ 092 enhances the efficacy of paclitaxel, lapatinib, trastuzumab, trametinib, and ARQ 087 both in cancer cell lines and mouse xenograft cancer models
Yu, Yi, Meade, Justin, Wick, Michael J., Terence, Hall, Eathiraj, Sudhi, Schwartz, Brian, Abbadessa, Giovanni
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article
Abstract 4808: Combinations of imatinib mesylate with AKT inhibitor (miransertib, ARQ 751) or FGFR inhibitor (derazantinib) show synergy in GIST cell lines and preclinical models
Kozinova, Marya, Joshi, Shalina, Devarajan, Karthik, Zook, Phillip, D'Souza, Jimson W., Farma, Jeffrey M., Esnaola, Nestor, Foroughi, Reza, Yu, Yi, Schwartz, Brian, Hall, Terence, Mehren, Margaret von, Rink, Lori A.
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article
Abstract 793: The novel Bruton's tyrosine kinase inhibitor ARQ531 disrupts survival signaling and triggers apoptosis in AML cells
debora, soncini, orecchioni, stefania, cagnetta, antonia, retali, veronica, ruberti, samantha, minetto, paola, contini, paola, nencioni, alessio, monacelli, fiammetta, Hall, Terence, gobbi, marco, eathiraj, sudharshan, schwartz, briam, bertolini, francesco, lemoli, roberto, cea, michele
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article